Introduction
Prostate cancer is the most common malignancy diagnosed in men of all ages in the USA, with 57.5% of new cases diagnosed in men aged 65 yr and a median age at diagnosis of 66 yr [1] [2] [3] At the time of diagnosis, considerable emphasis is placed on integrating health-related quality-of-life (QOL) considerations into treatment decisions, which may be even more important in older patients who may have lower baseline QOL [4, 5] . Knowledge about the varied effects of prostate cancer treatment modality on QOL domains can help to inform patients about the potential impact of a given treatment type and may improve treatment decision-making by allowing the physician to uniquely personalize counseling to reflect each patient's treatment preferences and objectives [6] [7] [8] [9] . It is known that patient age also strongly influences treatment decision-making. Studies have shown that older men are less likely to receive potentially curative local therapy at any level of disease risk, perhaps in part because of fears about QOL outcomes after treatment for older patients [10] [11] [12] . However, older men are more likely to be diagnosed with high-risk disease and these individuals face a higher risk of cancer-specific mortality in the absence of local therapy [13] [14] [15] . Despite this, older men have comparable outcomes and cancer control after treatment for localized disease [16, 17] . Therefore, the potential impact of treatment on QOL must be measured against the individualized risk of progressive cancer.
The associations between age and QOL outcomes after treatment in contemporary practice are not well defined [10, 18, 19] . Our objective was to describe QOL in men before and after primary treatment for prostate cancer, examining the impact of age on QOL outcomes. We hypothesized that while older men may have lower absolute function and bother at baseline and follow-up compared to younger men, declines in QOL after treatment would be less meaningful to older men, particularly in regard to their bother scores. To investigate, we performed a retrospective review of a prospectively maintained, nationwide, largely communitybased prostate cancer registry with longitudinal QOL follow-up.
Patients and methods
Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) is a prospective, longitudinal, observational study of men with biopsyproven prostate cancer [1, 3] . CaPSURE includes data on men treated at 43 community-based, academic, and veterans' practices nationwide. (3) (4) (5) , or high (6-10) risk [4] . Age at diagnosis was categorized into three subgroups (<60, 60-70, >70 yr) for assessment.
Prior studies have used similar age groupings to assess the impact of age on QOL [6] and have identified the 60-yr age group as a population at high risk of treatment-related effects on QOL [10] , prompting our evaluation for these age categories.
General QOL outcomes were assessed using the mental health and physical function scales from the RAND 36-item short-form health survey (SF-36), a well-validated, widely used measure of physical and mental well-being [13] . Treatment-specific QOL was reported via the UCLA Prostate Cancer Index (PCI), which measures function and bother for urinary, sexual, and bowel domains [20] . Scores for all SF-36 and PCI domains range from 0 to 100, with higher scores representing better QOL. Outcomes were defined as changes in QOL scores over time from baseline up to 2 yr after treatment.
Demographics, clinical characteristics, and QOL scores were compared between age groups using the Mantel-Haenszel x 2 test for trends for categorical variables. QOL changes over time between age groups were assessed using repeated-measures mixed models in which the independent variables included race, year of diagnosis, CAPRA score, type of primary treatment, number of comorbidities, age group, time, and time-age interaction. Least-square means for the age-time interaction term were used to assess whether the trajectory of QOL over time differed by age category, indicating whether younger men experienced the same pattern of change over 2 yr as older men. A set of secondary models with the same covariates addressed three-way interactions among age, time, and primary treatment. The five primary treatment types were regrouped as local (RP, BT, EBRT) versus nonlocal treatment (ADT, AS/WW) for these additional models. We performed pairwise comparisons using the Tukey-Kramer method to adjust for multiple statistical testing. Least-square means with confidence intervals from the mixed models were graphed to illustrate adjusted changes over time.
We explored both continuous differences and the amount of decline for ease of clinical interpretation. Model covariates were selected a priori and assessed for interitem correlations. A p value <0.01 was considered significant. Analyses were performed using SAS 9.4 for Windows (SAS, Cary, NC, USA) and R statistical software (R Foundation, Vienna, Austria).
Results
Among 9945 men newly diagnosed with prostate cancer and enrolled prospectively in CaPSURE during 1999-2013, 8069 were diagnosed with localized disease and treated with RP, BT, EBRT, ADT, or AS/WW. Of those, 6522 (81%) reported QOL data within 2 yr and formed the study cohort ( Fig. 1 ). Among the study cohort, 5362 men had multiple QOL assessments within 2 yr and were included in repeatedmeasures analyses. Men who were excluded from analysis owing to a lack of QOL data had a similar age distribution, but fewer were Caucasian (76% vs 90%), clinical CAPRA risk was higher (14% vs 10% CAPRA 6), and fewer underwent RP (56% vs 44%) in comparison to the final analytic group (all p < 0.01; Supplementary Table 1) . Patient characteristics are listed in Table 1 . Of the patients, 27% were younger than 60 yr, 44% were 60-70 yr, and 29% were older than 70 yr. Older men tended to have higher biopsy Gleason grade, PSA at diagnosis, and clinical CAPRA scores (all p < 0.01). Of the cohort, 44% underwent RP (of whom 2% had RP + EBRT), 29% received radiotherapy (of whom 48% had BT, 38% had EBRT, and 14% had BT + EBRT), 18% had primary ADT (of whom 68% were treated with a luteinizing hormone-releasing hormone agonist and 32% with an anti-androgen), and 10% enrolled in AS/WW (73% AS and 27% WW). Younger men underwent RP at a higher rate, whereas the oldest cohort of men more commonly underwent ADT or AS/WW.
At baseline, mean unadjusted physical function, urinary, and bowel scores were all 85, higher than the scores for mental health (79), sexual function (52), and sexual bother (61) for all ages combined (Table 2) . Age was associated with all QOL scores ( p < 0.01), with younger patients reporting higher scores for all domains except mental health. Baseline sexual, urinary, and physical outcomes differed across age groups by more than 10%. Treatment type was associated with all QOL measures except mental health ( p < 0.01), but only sexual function, sexual bother, and physical function differed by more than 10% across treatment groups. Men who underwent RP (mean age 61 yr, standard deviation [SD] 6.9 yr) had better baseline scores in these domains than the other treatment groups (combined mean age 71 yr, SD 7.9 yr).
Over time, QOL differed by age group for all domains (all p < 0.01) in multivariate analyses adjusted for age at diagnosis, time since baseline, age-time interaction, race, number of comorbidities reported at diagnosis, clinical CAPRA score, year of diagnosis, and type of primary treatment (Fig. 2) . For sexual and urinary outcomes, younger men had higher baseline scores, which declined at 1 yr, and then recovered somewhat better by 2 yr, although not to baseline levels. Bowel function and bother remained relatively stable for patients of all ages, except for the >70-yr age group, who reported less improvement in bother. Mental health scores started and remained highest for the >70-yr age group, but overall there was little change over the 2-yr period across all age groups. By contrast, baseline scores for physical function were lowest for the >70-yr age group and decreased at 2 yr in this group, but increased slightly for the other age groups.
Adjusted QOL means showed larger declines from baseline to 2 yr regardless of age group for the domains of sexual function (40-46%), sexual bother (17-39%), and urinary function (9-14%; Fig. 3 and Supplementary Table 2 ). More men aged <60 yr than men >70 yr experienced a decline at 2 yr in the domains of urinary function (14% vs 9%) and sexual bother (39% vs 17%). While a greater percentage of younger patients experienced a decline in sexual function at 1 yr (<60 yr 54% vs 60-70 yr 52% vs >70 yr 42%), fewer reported an overall decline in sexual function by 2 yr (<60 yr 40% vs 60-70 yr 44% vs >70 yr 46%).
Secondary analyses of treatment impact (local vs nonlocal treatment) on QOL demonstrated that the domains most affected were sexual function, sexual bother, and urinary function, with larger declines after local compared to nonlocal treatment, depending on age. At 2 yr, more men aged <60 yr experienced a decline in adjusted mean sexual function after local than after nonlocal treatment (42% vs 34%), while rates of decline for men aged >70 yr were similar for the treatment groups (43% vs. 45%). Adjusted mean scores for sexual bother worsened after local versus nonlocal treatment both for men aged <60 yr (41% vs. 25%) and men aged >70 yr (18% vs 12%). Declines in urinary function were also associated with local treatment, with men aged <60 yr, 60-70 yr, and >70 yr reporting declines of 15%, 14%, and 11%, respectively.
Discussion
We found that age was associated with sexual and urinary changes in QOL after treatment for localized prostate cancer. Previous studies have found that younger age at the time of treatment is associated with higher QOL function scores after treatment [21, 22] . Indeed, our data confirm that older men had lower unadjusted QOL scores both before and after treatment for all domains except mental health. However, our results show that younger and older men did not necessarily experience QOL declines in the same ways. While fewer men aged <60 yr compared to men >70 yr reported adjusted QOL declines in sexual function at 2 yr after treatment (40% vs 46% decline), they were more prone to worsening sexual bother than older men at 2 yr (39% vs 17%). This may indicate that because older men start with lower baseline QOL scores, they have lower recovery expectations than younger patients, or that older patients have developed greater resilience to QOL fluctuations over time [23] . In the
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CaPSURE prostate cancer patients as of November 2013 n = 14 715
Excluded because of diagnosis before 1999 or retrospective enrollment n = 4770
Newly diagnosed in1999 or later and prospectively enrolled n = 9945
Excluded because of nonlocalized disease n = 947
Localized disease (no cN1/M1/T4) n = 8998
Excluded because of alternative treatments n = 929
Primary treatment RP, BT, EBRT, ADT, or AS/WW n = 8069
Completed quality-of-life questionnaires n = 6522
Excluded because of lack of patientreported questionnaire data n = 1547
Completed multiple questionnaires within 2 yr after treatment n = 5362
Excluded because of lack of repeat patient-reported questionnaire data n = 1160 0 1 5 ) 4 8 0 -4 8 6 other QOL domains, however, there were only slight differences in the declines experienced between age groups. Further exploration of all domains using three-way age-QOL-treatment interactions yielded data supporting previous studies that suggest that local treatments such as RP have an effect on QOL, depending on age [23] [24] [25] . Men undergoing local treatment tended to have lower QOL post-treatment scores and greater declines in terms of urinary function in comparison to the nonlocal treatment group across all age groups. However, differences in sexual outcomes were more age-specific; younger men had greater declines and better recovery in function but experienced more bother over time than older men. These results suggest that treatment modality should be selected for patients according to their individualized baseline characteristics, quality of life, and treatment objectives rather than merely their age.
This study has several limitations, such as its observational study design. Among 8069 men who were eligible for 290 (17) 525 (19) 384 (21) 7 (4 + 3) 126 (7) 261 (9) 235 (13) 8-10 84 (5) 218 (8) [ ( F i g . _ 2 ) T D $ F I G ] inclusion, 66% completed pre-and postoperative QOL questionnaires necessary for analysis. However, men who were excluded from evaluation because of a lack of complete data had a similar mean age to our study population, differing only by the proportion of CAPRA 6 (14% vs 10%), race (76% vs 90% Caucasian ethnicity), and treatment type (56% vs 44% RP; all p < 0.01). Given that CAPRA risk and race are rarely be associated with risk of QOL declines, and that the mean age of the groups was similar, we feel that our analysis is representative of the larger cohort [26] . Our analysis used cutpoints to define categorical age groups. Age cutoffs can be difficult to determine, particularly when relying on chronologic age, but we selected these categories based on previous studies that have used similar groupings, and consider them to be representative of the population receiving treatment for localized prostate cancer. Finally, we were unable to reflect irritative and obstructive urinary symptoms using the UCLA PCI. Because the prevalence of benign prostatic hypertrophy increases with age and moderate to severe lower urinary tract symptoms are commonly identified in older men, the inability to evaluate these symptoms limited our conclusions for this domain [27] .
The study also has a number of strengths, including the use of well-validated and widely used patient-reported surveys to assess QOL after treatment for prostate cancer. In addition, we used a large prostate cancer registry with 2-yr follow-up of more than 5000 men representing a wide array of practice types. Finally, we present our findings as both adjusted means and percentage change to enable readers to consider both statistical significance and clinical relevance.
The implications of these findings are significant; providers should use these data to better inform patients about treatment choices and to discuss the effect of age and type of treatment on future QOL. The data show that in most circumstances, age alone does not predict greater declines in QOL after treatment, and in some cases the opposite is the case. Therefore, treatment options for localized prostate cancer in older men should not be limited because of fears about declines in QOL after treatment. Regardless of chronological age, treatment decisions for men should be based on cancer risk, overall health, and life expectancy, as well as patient preferences for treatment characteristics and prioritization of QOL domains.
Conclusions
Age has a variable effect on QOL after treatment of localized prostate cancer according to the QOL domain and type of treatment. Understanding these nuances is important when discussing treatment options with patients. Determining a patient's own QOL priorities after treatment should be an integral part of this discussion to help in individualizing management choices. Ultimately, this approach necessitates taking QOL into account regardless of age, whether to Funding/Support and role of the sponsor: None.
